AUPH Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -3.74%, SMA50 -7.24%, SMA200 14.38%). The stock’s 14-day RSI is 37.46 (weak momentum), while the ATR of 0.5 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -15.54% below its high and over 113.28% above its low. Average 10-day trading volume of 1.48 million shares is slightly above the 3-month average of 1.13 million, indicating heightened recent market interest.

Wall Street analysts project EPS growth of 197.2% annually over the next five years. The latest quarter delivered EPS of $0.25. The next quarter is forecast at $0.22. Next year's EPS is expected at $29.71. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 2 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $21.00 to $9.00. The high target offers 32.58% upside. The low target suggests -43.18% downside. The mean target is $15.60. This offers -1.52% upside. Aurinia Pharmaceuticals Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 07, 2026, missed forecasts by 38.89%. The prior quarter beat by 23.81%. Over the last six quarters, Apple has recorded several small beats. These include 200.0% in February 27, 2025.

Aurinia Pharmaceuticals Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $6.60. This means the shares are trading above this model’s fair value.

Aurinia Pharmaceuticals Inc. has 132.97 million shares outstanding. The public float is 128.74 million shares, elevated short interest at 8.36% of float. This equals 10.16 million shares. The short ratio is 9.72 days. Institutional investors hold 54.66% of the float. Insiders own 7.14%. TANG KEVIN holds 12.23 million shares, Greenleaf Peter has 1.52 million shares and Donley Matthew Maxwell has 584.07 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) closed at $15.84 USD, losing -$0.19 (-1.19%) from the previous close of $16.03. The stock is currently mid-range between its 52-week high and low $7.29 and $16.88. With a market capitalization of about $2.04 billion, Aurinia Pharmaceuticals Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~1.45). Key stats such as the average daily volume over the past year has been around 1.16 million shares, in line with its 52-week average. Headquartered in Edmonton, BC, Aurinia Pharmaceuticals Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Kevin C. Tang, the company employs approximately 130 people and listed since September 03, 2014. Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally.

Aurinia Pharmaceuticals Inc. trades at a P/E ratio of 7.06, slightly below the S&P 500 average, with a price-to-sales ratio of 6.86 and a price-to-book ratio of 3.71 trading at moderately above to book value. The P/FCF stands at 12.36, also below market averages.

Our AI price prediction model suggests that Aurinia Pharmaceuticals Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.2%, with price expected at $15.65 by May 28, 2026, within a range of $15.24 to $16.08 3-Month Outlook: Projected rise of 27.02%, reaching $20.12 by August 12, 2026, with a range of $19.86 to $20.42. 1-Year Outlook: Projected gain of 14.71%, with price at $18.17 by May 14, 2027, within a range of $17.39 to $19.41.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares are flat -7.27% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Aurinia Pharmaceuticals Inc. trading at a premium to the broader market with a P/E of 7.06. Analyst sentiment is cautious, with the majority of ratings in Market Perform territory and a mean price target of $16.80, suggesting 6.06% upside. Our AI forecast model points to short-term weakness (-1.2% over two weeks), a medium-term rise (27.02% over three months), and a longer-term gain (14.71% over one year), with expected trading ranges indicating moderate volatility.